Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 35
Filtrar
Más filtros

País/Región como asunto
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
BMC Infect Dis ; 22(1): 267, 2022 Mar 19.
Artículo en Inglés | MEDLINE | ID: mdl-35305563

RESUMEN

BACKGROUND: The association between H. pylori (Helicobacter pylori) infection and gastroesophageal reflux disease (GERD) is a complex and confusing subject. The aim of this study was to evaluate the association between helicobacter pylori infection and erosive gastroesophageal reflux disease. METHOD: In a cross-sectional study, all patients referred for endoscopy due to dyspepsia were enrolled. The diagnosis of erosive GERD was made by endoscopy. Patients with normal esophagus were selected as comparison group. Random gastric biopsies were taken from all participants to diagnose H. pylori infection. RESULT: In total, 1916 patients were included in this study, of whom 45.6% had GERD. The mean age (SD) was 42.95 (16.32). Overall, 1442 (75.3%) patients were positive for H. pylori infection. The frequency of H. pylori infection in mild GERD patients was higher than the severe GERD, but this difference was not significant (P = 0.214). Except for sociodemographic status (P < 0.001), other variables including gender, age, ethnicity, body mass index (BMI), smoking, and presence of hiatus hernia in patients had no significant association with the frequency of H. pylori infection. According to Robust Poisson regression models analysis, the association of H. pylori (PR 1.026; 95% CI 0.990-1.064; P = 0.158) and sociodemographic status were not significantly different between the two groups. But smoking, increased BMI, older age, presence of hiatus hernia, and peptic ulcer diseases were significantly associated with GERD compared with the non-GERD group. CONCLUSION: In our results, there was no association between H. pylori infection and erosive GERD. Further studies are recommended.


Asunto(s)
Dispepsia , Reflujo Gastroesofágico , Infecciones por Helicobacter , Helicobacter pylori , Estudios Transversales , Dispepsia/complicaciones , Reflujo Gastroesofágico/complicaciones , Reflujo Gastroesofágico/diagnóstico , Reflujo Gastroesofágico/patología , Infecciones por Helicobacter/complicaciones , Infecciones por Helicobacter/diagnóstico , Humanos
2.
Pak J Med Sci ; 31(6): 1511-6, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-26870126

RESUMEN

OBJECTIVES: Ulcerative Colitis (UC) follows a natural clinical course of relapses and remissions. The aim of this study was to construct a risk-scoring formula in order to enable predicting relapses in patients with UC. METHODS: From October 2012 to October 2013, 157 patients from Shiraz, southern Iran who were diagnosed with UC and in remission were enrolled. At 3-month intervals, multiple risk factors of hemoglobin, complete blood counts, serum iron and albumin, erythrocyte sedimentation rate, and faecal calprotectin levels, sex, age, cigarette smoking, positive family history of inflammatory bowel diseases, past history of appendectomy, extra-intestinal accompanying diseases, extent of disease at the beginning of study, number of previous relapses, duration of disease and duration of remission before the study were assessed. Univariate and multivariate logistic regression were applied to fit the final model. The new risk-scoring system accuracy was assessed using receiver-operating-characteristics (ROC) curve analysis. RESULTS: Seventy four patients (48.1%) experienced a relapse. Multivariate analysis revealed that relapses could significantly be predicted by the level of fecal calprotectin (OR=8.1), age (OR=9.2), the Seo activity index (OR=52.7), and the number of previous relapses (OR=4.2). The risk scoring formula was developed using the regression coefficient values of the aforementioned variables. CONCLUSION: Four predictor variables were significant in the final model and were used in our risk-scoring formula. It is recommended that patients who achieve high scores are diligently observed, treated, and followed up.

3.
Artículo en Inglés | MEDLINE | ID: mdl-38172464

RESUMEN

INTRODUCTION: Biliary complications (BCs) are a well-documented post-liver transplantation concern with potential implications for patient survival. This study aims at identifying risk factors associated with the development of BCs in recipients after liver transplantation (LT) and exploring strategies for their management. METHODS: We conducted a retrospective analysis of 1595 adult patients (age > 18 years) who underwent LT surgery between 2019 and 2021. The study assessed the incidence of BCs in this cohort. RESULTS: Of 1595 patients, 178 (11.1%) experienced BCs, while 1417 (88.8%) did not exhibit any signs of such complications. Patients who developed BCs were found to have a significantly lower average age (p < 0.001) and longer cold ischemic times (p < 0.001) compared to those without BCs. Variables such as sex, body mass index (BMI), model for end-stage liver disease (MELD) score, primary diagnosis, type of anastomosis, hepatectomy technique, type of transplanted liver and mortality did not demonstrate statistically significant differences between the two groups (p > 0.05). Univariate logistic regression analysis revealed that a cold ischemic time exceeding 12 hours and duct-to-duct anastomosis were positive predictors for BC development (odds ratios of 6.23 [CI 4.29-9.02] and 1.47 [CI 0.94-2.30], respectively). Conversely, increasing age was associated with a protective effect against BC development, with an odds ratio of 0.64 (CI 0.46-0.89). CONCLUSION: Our multi-variate analysis identified cold ischemia time (CIT) as the sole significant predictor of post-liver transplantation biliary complications. Additionally, this study observed that advancing patient age had a protective influence in this context. Notably, no significant disparities were detected between hepatectomy techniques and the etiology of liver disease types in the two study groups.

4.
Clin Transplant ; 25(4): 638-45, 2011.
Artículo en Inglés | MEDLINE | ID: mdl-21077951

RESUMEN

The current policy for organ allocation in liver transplantation is to give priority to the sickest patients mostly using model for end-stage liver disease (MELD) score in ranking. However, other factors as serum sodium may be of value in predicting early mortality. In this single-center study, patients with cirrhosis over age 14 on the liver transplant wait-list from September 1998 to June 2007 were followed for six months from the time of listing to evaluate the value of hyponatremia on mortality. Of 612 listed patients, 51 were transplanted who were excluded from survival analysis and 55 died without transplantation within the first three months. The numbers of transplanted and dead patients during months 3-6 were 29 and 24, respectively. Both MELD score and serum sodium at the time of listing were independent predictors of early mortality. On bivariate analysis, serum sodium of <130 mEq/L beside MELD was a significant predictor of mortality within 90 and 180 d. Serum sodium level <135 mEq/L masked the difference in mortality between patients with refractory and non-refractory ascites. Serum sodium level of <130 mEq/L and an increased MELD score are significant predictors of early mortality in patients listed for liver transplantation.


Asunto(s)
Rechazo de Injerto/etiología , Hiponatremia/diagnóstico , Hiponatremia/etiología , Cirrosis Hepática/mortalidad , Trasplante de Hígado/mortalidad , Adolescente , Adulto , Anciano , Estudios de Cohortes , Enfermedad Hepática en Estado Terminal/terapia , Femenino , Estudios de Seguimiento , Rechazo de Injerto/mortalidad , Supervivencia de Injerto , Humanos , Hiponatremia/sangre , Cirrosis Hepática/complicaciones , Cirrosis Hepática/diagnóstico , Fallo Hepático , Trasplante de Hígado/efectos adversos , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Sodio/sangre , Tasa de Supervivencia , Donantes de Tejidos , Resultado del Tratamiento , Listas de Espera , Adulto Joven
5.
Indian J Gastroenterol ; 40(3): 281-286, 2021 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-33743161

RESUMEN

BACKGROUND/PURPOSE: Budd-Chiari syndrome (BCS) is a rare, life-threatening disease characterized by hepatic venous outflow obstruction. Liver transplantation (LT) is widely accepted as an effective therapeutic measure for irreversible liver failure due to BCS. There is debate on differences in the post LT course and complications in patients with BCS as compared to non-Budd-Chiari (NBC) patients. METHOD: In this retrospective study, data on all patients who received a liver transplant for BCS at the Shiraz Organ Transplantation Center between January 1996 and September 2017 were reviewed and compared to data of a control group who had received liver transplants over the same period but due to other causes (NBC). RESULTS: Out of 4225 patients who received liver transplants in the study period, 108 had BCS and an age- and gender-matched control group consisted of 108 NBC cases. The mean ± standard deviation (SD) of model for end-stage liver disease (MELD) scores were 19.1 ± 3 and 20 ± 3 for BCS and NBC groups, respectively (p = 0.33). One-, 3-, 5-, and 10-year survival rates in the BCS group were as follows: 82%, 78%, 76%, and 76% compared with the NBC rates of 83%, 83%, 83%, and 76%, respectively (p = 0.556). There was no difference between the two groups in complication rates after 6 months. In the later period, vascular thrombosis was more common in BCS. CONCLUSIONS: Whole-organ LT from deceased donors in patients with BCS had comparable outcomes with LT due to other causes of end-stage liver disease. In most instances, these patients should receive lifelong anticoagulation.


Asunto(s)
Síndrome de Budd-Chiari , Enfermedad Hepática en Estado Terminal , Trasplante de Hígado , Síndrome de Budd-Chiari/etiología , Enfermedad Hepática en Estado Terminal/cirugía , Humanos , Estudios Retrospectivos , Índice de Severidad de la Enfermedad
6.
Scand J Gastroenterol ; 45(10): 1162-7, 2010 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-20568969

RESUMEN

OBJECTIVE: Helicobacter pylori infection is accompanied by inflammatory processes leading to peptic ulcer and gastric cancer in the minority of infected individuals. The interaction between H. pylori virulence factors, host defense mechanisms and environmental factors determine the outcome of clinical manifestations. One of the host factors involved in the processes of inflammation and carcinogenesis is the peroxisome proliferator-activated receptor-γ (PPAR-γ) molecule. The present case-control study aimed to determine polymorphism of PPAR-γ gene and its association with H. pylori infection and gastrointestinal diseases (peptic ulcer and non-cardia gastric cancer) in Iranian patients. MATERIALS AND METHODS: One hundred and fifty-five patients with upper gastrointestinal diseases (76 peptic ulcer and 79 non-cardia gastric cancer) and 152 matched controls were genotyped for PPAR-γ gene polymorphism (Pro12Ala) by the PCR-RFLP method. Infection with H. pylori was confirmed by histology, the rapid urease test (RUT) and ELISA assay (IgG anti-H. pylori). RESULTS: The frequency of PPAR-γ G (Ala 12) allele was significantly higher in H. pylori positive patients with non-cardia gastric cancer than in controls (22.8% vs. 3.9%, p = 0.027; OR = 3.28; 95% CI = 1.21-8.89), But there was no significant difference without infection (p = 0.7). Moreover, the PPAR-γ polymorphism was not associated with peptic ulcer in the presence or absence of H. pylori infection. CONCLUSION: Our results indicated PPAR-γ G allele may be an important contributor to non-cardia gastric cancer in Iranian H. pylori infected patients.


Asunto(s)
Adenocarcinoma/genética , Adenocarcinoma/microbiología , Infecciones por Helicobacter/complicaciones , Helicobacter pylori , PPAR gamma/genética , Polimorfismo de Nucleótido Simple , Neoplasias Gástricas/genética , Neoplasias Gástricas/microbiología , Adenocarcinoma/epidemiología , Estudios de Casos y Controles , Femenino , Marcadores Genéticos/genética , Genotipo , Infecciones por Helicobacter/epidemiología , Humanos , Irán/epidemiología , Masculino , Persona de Mediana Edad , Úlcera Péptica/epidemiología , Úlcera Péptica/genética , Úlcera Péptica/microbiología , Neoplasias Gástricas/epidemiología
7.
Int J Colorectal Dis ; 25(3): 389-94, 2010 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-19705134

RESUMEN

PURPOSE: Although colchicine has been tested in clinical trials for treatment of constipation, the index groups in those trials were composed of special patient groups with developmental neuromuscular defects or failed surgical management. The aim of this study is to investigate the efficacy of colchicine in patients with refractory slow transit constipation. MATERIALS AND METHODS: Sixty patients with chief complaint of chronic constipation due to slow transit consented to be included in the double-blind placebo-controlled clinical trial. These patients were randomly divided into two groups (each containing 30 patients) to receive either colchicine, 1 mg QD, (group A) or placebo (group B) for 2 months. At the end of the study, Knowles-Eccersly-Scot symptom (KESS, a valid technique to assist in the diagnosis and evaluation of symptoms in constipation) scores were compared between the case and control groups. RESULTS: The mean KESS score measured at the end of 2 months was 11.67 +/- 3.91 for colchicine and 18.66 +/- 3.72 for placebo group (p = 0.0001). CONCLUSION: This trial shows that low-dose colchicine is effective in treatment of slow transit constipation.


Asunto(s)
Colchicina/uso terapéutico , Estreñimiento/tratamiento farmacológico , Estreñimiento/fisiopatología , Tránsito Gastrointestinal/fisiología , Moduladores de Tubulina/uso terapéutico , Adulto , Demografía , Método Doble Ciego , Femenino , Humanos , Masculino , Placebos , Factores de Tiempo
8.
Indian J Pharmacol ; 52(2): 86-93, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-32565595

RESUMEN

OBJECTIVES: The aim of this study is to investigate the therapeutic property of hydroalcoholic extract of Fenugreek seeds in nonalcoholic fatty liver disease (NAFLD) in adult patients. METHODS: This randomized, placebo-controlled, parallel trial was conducted from November 2014 to June 2017. Patients aged between 18 and 70 years old with confirmed NAFLD were recruited from the Motahhari clinic, affiliated to Shiraz University of Medical Sciences, Iran. Participants either received 1 g hydroalcoholic extract of Fenugreek seeds or placebo daily for 3 months. The primary outcomes were changes in serum alanine transaminase and FibroScan controlled attenuation parameter score. Secondary outcome measures were changes in other laboratory data, liver stiffness measure, liver steatosis percent, and anthropometric variables. Participants were randomly assigned to the groups using blocked randomization method. Participants, investigators, and statistician were blinded to treatments allocation. RESULTS: After screening eighty patients, thirty patients met the inclusion criteria and were divided into two groups (1:1). After 3 months, two and four patients did not complete the trial in Fenugreek and placebo group, respectively. The changes in the anthropometrics, laboratories and FibroScan measurements were not statistically significant between the two groups. CONCLUSION: The evidence to prove the efficacy of the Fenugreek seeds' hydroalcoholic extract in NAFLD was not strong enough; hence, further experiments are still needed to assess the possible efficacy of Fenugreek on the treatment of NAFLD.


Asunto(s)
Hígado/efectos de los fármacos , Enfermedad del Hígado Graso no Alcohólico/tratamiento farmacológico , Extractos Vegetales/uso terapéutico , Semillas , Trigonella , Adulto , Alanina Transaminasa/sangre , Biomarcadores/sangre , Femenino , Humanos , Irán , Hígado/diagnóstico por imagen , Hígado/metabolismo , Masculino , Persona de Mediana Edad , Enfermedad del Hígado Graso no Alcohólico/sangre , Enfermedad del Hígado Graso no Alcohólico/diagnóstico por imagen , Proyectos Piloto , Extractos Vegetales/efectos adversos , Extractos Vegetales/aislamiento & purificación , Semillas/química , Solventes/química , Factores de Tiempo , Resultado del Tratamiento , Trigonella/química
9.
Dig Dis Sci ; 54(3): 599-603, 2009 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-18594971

RESUMEN

This study compared a new regimen (group A: doxycycline, co-amoxiclav, omeprazole) and two routinely prescribed regimens (group B: amoxicillin, omeprazole, furazolidone, bismuth; group C: amoxicillin, clarithromycin, omeprazole) to find an acceptable first-line treatment option for Helicobacter pylori. The study population consisted of 189 patients who referred to our clinic to undergo endoscopy due to ulcer-like dyspepsia. The H. pylori eradication rate was 68% in group A, 56% in group B, and 70% in group C according to per-control analysis. There was no statistically significant difference in H. pylori eradication between groups A and B (P = 0.187), groups A and C (P = 0.857), and groups B and C (P = 0.15). In conclusion, although none of the three eradication regimens can be recommended as a first-line eradication treatment, the new regimen is at least as effective and probably better tolerated than the two routinely applied regimens.


Asunto(s)
Combinación Amoxicilina-Clavulanato de Potasio/uso terapéutico , Antibacterianos/uso terapéutico , Antiulcerosos/uso terapéutico , Doxiciclina/uso terapéutico , Infecciones por Helicobacter/tratamiento farmacológico , Omeprazol/uso terapéutico , Método Doble Ciego , Quimioterapia Combinada , Femenino , Helicobacter pylori/efectos de los fármacos , Humanos , Irán , Masculino , Resultado del Tratamiento
10.
Dig Dis Sci ; 54(9): 1966-70, 2009 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-19009348

RESUMEN

This study aimed to determine the relation between Helicobacter pylori infection and insulin resistance in healthy subjects. In a cross-sectional case control study between January and April 2007, a total of 71 healthy subjects without the exclusion criteria completed the study. Forty-three (60.6%) patients were H. pylori positive and 28 (39.4%) patients were H. pylori negative. Age and body mass index of the patients were not significantly different between the two groups (32.2 +/- 14.2 vs. 33 +/- 8.05 years and 23.15 +/- 4.5 vs. 24.04 +/- 3.2 kg/m(2), respectively). H-pylori-positive patients had significantly higher HOMA-IR level compared to H-pylori-negative patients (3.54 +/- 2.2 vs. 2.46 +/- 1.9, respectively) (P < 0.05). Fasting serum insulin level was significantly higher in the H-pylori-positive group compared with the H-pylori-negative group (19.41 +/- 3.08 vs. 16.57 +/- 2.02 microU/ml, respectively) (P < 0.05). Our findings suggest recognition of H. pylori infection as a risk factor for insulin resistance.


Asunto(s)
Infecciones por Helicobacter/fisiopatología , Resistencia a la Insulina , Adolescente , Adulto , Anticuerpos Antibacterianos/sangre , Estudios de Casos y Controles , Estudios Transversales , Femenino , Helicobacter pylori/inmunología , Humanos , Masculino , Persona de Mediana Edad , Factores de Riesgo , Adulto Joven
11.
Can J Gastroenterol ; 23(2): 105-8, 2009 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-19214285

RESUMEN

BACKGROUND: Diagnosis and localization of intestinal metaplasia and early gastric cancer is problematic because of the lack of any telltale gross endoscopic signs. OBJECTIVE: To compare the efficacy of chromoendoscopy with conventional endoscopy for the detection of gastric premalignant lesions (intestinal metaplasia). METHOD: Thirty-three patients in whom previous routine endoscopic biopsies showed intestinal metaplasia were enrolled in a prospective study. Each patient underwent a two-step endoscopy procedure: conventional endoscopy and chromoendoscopy using methylene blue. Biopsies were taken during each step and were studied by an expert pathologist. Presence of intestinal metaplasia was considered a positive result. RESULTS: Considering the presence of intestinal metaplasia anywhere in the stomach as a positive result, 13 patients were diagnosed with intestinal metaplasia using both endoscopic methods, while eight patients had positive results using chromoendoscopy without any metaplastic changes detected with the conventional method (P=0.003). One patient showed positive biopsies with the conventional method while the pathology report showed no positive biopsies using the chromoendoscopy method. The number of positive biopsies from the antrum, body and fundus were 18, 15 and seven, respectively, using chromoendoscopy, and 10, four and two, respectively, from the same sites using conventional endoscopy. CONCLUSION: The present study demonstrated that chromoendoscopy is superior to conventional endoscopy for the detection of metaplastic changes and its use can be suggested for the screening of early malignancies of the stomach.


Asunto(s)
Gastroscopios , Gastroscopía/métodos , Lesiones Precancerosas/diagnóstico , Neoplasias Gástricas/diagnóstico , Neoplasias Gástricas/patología , Adulto , Diseño de Equipo , Femenino , Humanos , Masculino , Metaplasia/diagnóstico , Azul de Metileno , Persona de Mediana Edad , Reproducibilidad de los Resultados , Sensibilidad y Especificidad , Estómago/patología
12.
Can J Gastroenterol ; 23(10): 699-704, 2009 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-19826646

RESUMEN

BACKGROUND/OBJECTIVE: Several combination endoscopic therapies are currently in use. The present study aimed to compare argon plasma coagulation (APC) + adrenaline injection (AI) with hemoclips + AI for the treatment of high-risk bleeding peptic ulcers. METHODS: In a prospective randomized trial, 172 patients with major stigmata of peptic ulcer bleeding were randomly assigned to receive APC + AI (n = 89) or hemoclips + AI (n = 83). In the event of rebleeding, the initial modality was used again. Patients in whom treatment or retreatment was unsuccessful underwent emergency surgery. The primary end point of rebleeding rate and secondary end points of initial and definitive hemostasis need for surgery and mortality were compared between the two groups. RESULTS: The two groups were similar in all background variables. Definitive hemostasis was achieved in 85 of 89 (95.5%) of the APC + AI and 82 of 83 (98.8%) of the hemoclips + AI group (P = 0.206). The mean volume of adrenaline injected in the two groups was equal (20.7 mL; P = 0.996). There was no significant difference in terms of initial hemostasis (96.6% versus 98.8%; P = 0.337), rate of rebleeding (11.2% versus 4.8%; P = 0.124), need for surgery (4.5% versus 1.2%; P = 0.266) and mortality (2.2% versus 1.2%; P = 0.526). When compared for the combined end point of mortality plus rebleeding and the need for surgery, there was an advantage for the hemoclip group (6% versus 15.7%, P = 0.042). CONCLUSION: Hemoclips + AI has no superiority over APC + AI in treating patients with high-risk bleeding peptic ulcers. Hemoclips + AI may be superior when a combination of all negative outcomes is considered.


Asunto(s)
Electrocoagulación/métodos , Epinefrina/administración & dosificación , Hemostasis Endoscópica , Úlcera Péptica Hemorrágica/terapia , Vasoconstrictores/administración & dosificación , Adulto , Anciano , Femenino , Hemostasis Endoscópica/instrumentación , Humanos , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Recurrencia , Resultado del Tratamiento
13.
Artículo en Inglés | MEDLINE | ID: mdl-30643831

RESUMEN

BACKGROUND: Self-management (SM) as a dynamic process enables Ulcerative colitis (UC) patients to live with this chronic illness. The present study aimed to investigate the effect of SM education on self-efficacy (SE) and quality of life (QoL) in patients with UC. METHODS: This randomized controlled clinical trial study was conducted on 64 patients with UC from December 2016 to February 2017 at Motahari clinic, Shiraz. Patients were randomly divided into two groups of intervention and control. The education program included six 90-minute sessions in 3 weeks and one month telephone follow-up. Before, immediately and one month after the intervention, the participants filled out the Strategies Used by People to Promote Health (SUPPH) for SE, and the Inflammatory Bowel Disease Questionnaire-9 (IBDQ-9) for Qol. Then, data were entered into SPSS 18.0 and analyzed using independent samples t-test, Chi-square, repeated measures ANOVA and Pearson's correlation coefficient. RESULTS: A significant increase was observed in terms of the overall mean score for SE and its dimensions in the intervention group (P<0.001). These scores were significantly higher than those of the control group (P<0.001), except for positive attitude (P=0.15). The scores for overall Qol and its dimensions significantly increased in the intervention group immediately and one month after the intervention (P<0.001), and the difference between the two groups was significant (P<0.001). There was a significant positive correlation between SE and Qol (r=0.32, P=0.01). CONCLUSION: SM improved the SE and Qol in patients with UC. SM educatoin is recommended in nursing care of patients with UC. Trial Registration Number: IRCT2016092429823N1.

14.
Risk Manag Healthc Policy ; 12: 349-355, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-31853206

RESUMEN

BACKGROUND AND STUDY AIM: Chronic use of proton-pump inhibitors (PPIs) has become a mainstay of therapy in common gastrointestinal diseases. A causal relationship between chronic PPI use and development of osteoporosis remains unproven. The aim of this study was to determine whether PPI users are more likely to develop alterations in bone density. PATIENTS AND METHODS: In an analytical cross sectional study, patients who used PPIs for more than 2 years because of long-term gastroesophageal reflux disease (GERD) were recruited. PPI users were healthy people except for GERD. The compression group was randomly derived from an age-, sex- and physical activity-matched group from a healthy population in the National Registry of Osteoporosis who had not used PPIs in the previous 2 years. Bone mineral density was measured with dual-energy X-ray absorptiometry. Data regarding BMD and bone mineral content (BMC) of three regions: femoral neck, total hip, and the lumbar spine (L1-L4) were gathered and recorded. The World Health Organization (WHO) classification was used for definition of osteopenia and osteoporosis. RESULTS: A total of 394 participants (133 PPI users and 261 comparison group) were enrolled. The median duration of PPI use was 6.7 (2-31) years. The mean age ± SD of PPI users and comparison group was 48.38 ± 11.98 and 47.86 ± years, respectively (P = 0.681). There was no significant difference in baseline characteristics and age distribution between the two groups. The BMC levels were significantly lower in PPI users in all three regions: lumbar spine, total hip, and femoral neck (P<0.001). There were no significant differences in the T-scores between the two groups except for femoral neck (P<0.001). Osteoporosis in femoral neck was significantly higher in PPI users than in comparison group. CONCLUSION: This study showed that long-term use of PPIs is associated with lower BMC and higher rate of osteoporosis in the femoral neck. However, more studies with longitudinal evaluation should be performed to clarify this causal relationship. Until then, it is advised not to overuse PPIs because of the possible increase in risk of osteoporosis and the risk of fractures. We also recommend using the BMC levels as a quantitative measure in addition to T scores in analysis and reporting similar studies.

15.
Clin Exp Hepatol ; 5(2): 161-168, 2019 May.
Artículo en Inglés | MEDLINE | ID: mdl-31501793

RESUMEN

AIM OF THE STUDY: Host and viral factors can influence the clinical course of chronic hepatitis B virus (HBV) infection. Mutations in pre-S1/S2 gene regions are among the most important viral factors determining the HBV infection outcome. The aim of this study was to investigate the role of pre-S1/S2 mutations in HBV infection outcome. MATERIAL AND METHODS: A total of 52 samples from 26 asymptomatic carriers (ASCs) and 26 liver cirrhosis/hepatocellular carcinoma (LC/HCC) patients were enrolled. The HBV DNA genome was extracted from the sera, and pre-S1/S2 regions of the samples were amplified by nested-polymerase chain reaction, prior to being subjected to sequencing, sequence investigation and phylogenetic analysis. RESULTS: Certain deletions were detected mostly located at the boundary of the pre-S1 and pre-S2 regions. These deletions were detected more frequently in ASC cases than in LC/HCC patients (p < 0.007). The rate of critical point mutations, including L11Q, N37S and K38R, was significantly higher in the ASC group, whereas the A49V substitution rate was significantly higher in the LC/HCC group (p < 0.05). The phylogenetic analysis indicated that all the sequences belonged to genotype D. CONCLUSIONS: According to the results, point mutations such as L11Q, N37S, K38R and A49V, as well as certain deletions, may be associated with HBV infection outcome, among an HBV genotype D pure population.

16.
Intest Res ; 17(3): 330-339, 2019 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-31006228

RESUMEN

BACKGROUND/AIMS: A recent study revealed increasing incidence and prevalence of inflammatory bowel disease (IBD) in Iran. The Iranian Registry of Crohn's and Colitis (IRCC) was designed recently to answer the needs. We reported the design, methods of data collection, and aims of IRCC in this paper. METHODS: IRCC is a multicenter prospective registry, which is established with collaboration of more than 100 gastroenterologists from different provinces of Iran. Minimum data set for IRCC was defined according to an international consensus on standard set of outcomes for IBD. A pilot feasibility study was performed on 553 IBD patients with a web-based questionnaire. The reliability of questionnaire evaluated by Cronbach's α. RESULTS: All sections of questionnaire had Cronbach's α of more than 0.6. In pilot study, 312 of participants (56.4%) were male and mean age was 38 years (standard deviation=12.8) and 378 patients (68.35%) had ulcerative colitis, 303 subjects (54,7%) had college education and 358 patients (64.74%) were of Fars ethnicity. We found that 68 (12.3%), 44 (7.9%), 13 (2.3%) of participants were smokers, hookah and opium users, respectively. History of appendectomy was reported in 58 of patients (10.48%). The most common medication was 5-aminosalicylate (94.39%). CONCLUSIONS: To the best of our knowledge, IRCC is the first national IBD registry in the Middle East and could become a reliable infrastructure for national and international research on IBD. IRCC will improve the quality of care of IBD patients and provide national information for policy makers to better plan for controlling IBD in Iran.

17.
Hepatogastroenterology ; 55(84): 1066-70, 2008.
Artículo en Inglés | MEDLINE | ID: mdl-18705329

RESUMEN

BACKGROUND/AIMS: Liver biopsy is a cornerstone in the management of chronic hepatitis patients. In biopsy, liver cell damage as well as severity of inflammatory cell infiltration in the parenchyma and portal tracts are evaluated. There are some other inflammatory markers such as complements (C) and immunoglobulins (Ig), which are involved in the pathogenesis of inflammation. This study was carried out to investigate the status of Ig and C depositions in the liver of chronic hepatitis cases. METHODOLOGY: Two biopsy samples were taken from patients who were scheduled for liver biopsy for chronic hepatitis. The acetone fixed sections were incubated with fluorescin-conjugated anti human IgG, IgA, IgM, C3 and C4. Ten samples of non-hepatitis control cases were provided during elective cholecystectomy. RESULTS: Deposition of IgG, IgM, and Cs were seen in the parenchyma in HBV, HCV and non viral hepatitis cases. The parenchyma of control liver did not show any deposition of IgG, IgM, and Cs. IgA was found in the parenchyma of 3 control cases. C3 deposition in the parenchyma had significant association with enzyme rising in HCV (p=0.001) and non viral groups (p=0.004). C4 deposition in the parenchyma was also associated with enzyme rising in HCV cases (p=0.01). There was an association between ALT elevations with the presence of IgM in the parenchyma in HBV (p=0.01) and HCV (p=0.03) groups. Mantel-Haenszel chi2 test (for evaluation of the effects of stage and grade) confirmed that the depositions of C3 and C4 in HCV and C3 in nonviral hepatitis have positive association with enzyme rising. CONCLUSIONS: Presence of IgM, IgG, C3, and C4 in the liver parenchyma is abnormal and may be helpful in histological evaluation in chronic hepatitis. Parenchymal (but not portal) depositions of C3 and C4 in HCV and non-viral hepatitis cases show close association with elevation of liver enzymes.


Asunto(s)
Complemento C3/metabolismo , Complemento C4/metabolismo , Hepatitis B Crónica/patología , Hepatitis C Crónica/patología , Hepatitis Crónica/patología , Inmunoglobulina G/metabolismo , Inmunoglobulina M/metabolismo , Adulto , Anciano , Biopsia , Femenino , Humanos , Inmunoglobulina A/metabolismo , Hígado/patología , Pruebas de Función Hepática , Masculino , Microscopía Fluorescente , Persona de Mediana Edad
18.
Indian J Gastroenterol ; 27(6): 236-8, 2008.
Artículo en Inglés | MEDLINE | ID: mdl-19405257

RESUMEN

Acute mesenteric ischemia (AMI) is a catastrophic disorder of the gastrointestinal tract with high mortality. Few data on the characteristics of this disease in Iran are available. Patient records of public and private hospitals in Shiraz, southern Iran, with impression of acute abdomen, bowel gangrene or abdominal pain, and patients with risk factors for this disease, who were admitted between March 1989 and March 2005, were reviewed. Among the 10,000 patient records studied, 105 patients (mean age 57 years) with AMI were identified. The mortality rate was 50.4%. The most common symptom was abdominal pain (98.1%). Heart diseases were seen in 44.7% of cases. The mortality rate was lower in patients undergoing mesenteric angiography (p=0.014). In those patients in whom the site of lesion was identified, venous thrombosis was the most common type (41.9%). AMI is a common cause of acute abdomen especially in elderly patients, with venous thrombosis being the most common type.


Asunto(s)
Oclusión Vascular Mesentérica/etiología , Oclusión Vascular Mesentérica/mortalidad , Enfermedad Aguda , Adulto , Diagnóstico por Imagen , Femenino , Humanos , Irán/epidemiología , Masculino , Oclusión Vascular Mesentérica/diagnóstico , Persona de Mediana Edad , Factores de Riesgo
19.
Expert Rev Gastroenterol Hepatol ; 12(6): 575-584, 2018 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-29781738

RESUMEN

INTRODUCTION: Primary sclerosing cholangitis (PSC) is a chronic inflammatory disease of the hepatobiliary system characterized by chronic inflammation, progressive fibrosis, stricture formation and destruction of extrahepatic and intrahepatic bile ducts. Areas covered: The increased incidence of cholangiocarcinoma (CCA) in PSC has been well documented and can be explained by the continuous inflammation in the biliary tree leading to an enhanced dysplasia-carcinoma sequence. Although PSC patients may progress to liver cirrhosis; CCA most commonly occurs between the ages of 30 and 45 years when cirrhosis has not yet developed. Therefore, CCA in patients with PSC occurs earlier than in patients without PSC. Expert commentary: Despite improvement in diagnostic methods and devices, the dilemma of diagnosing CCA in patients with PSC has not been solved yet and needs further investigation.


Asunto(s)
Neoplasias de los Conductos Biliares/diagnóstico , Transformación Celular Neoplásica/patología , Colangiocarcinoma/diagnóstico , Colangitis Esclerosante/diagnóstico , Adulto , Neoplasias de los Conductos Biliares/epidemiología , Neoplasias de los Conductos Biliares/patología , Colangiocarcinoma/epidemiología , Colangiocarcinoma/patología , Colangitis Esclerosante/epidemiología , Colangitis Esclerosante/patología , Progresión de la Enfermedad , Humanos , Cirrosis Hepática/diagnóstico , Cirrosis Hepática/epidemiología , Persona de Mediana Edad , Valor Predictivo de las Pruebas , Pronóstico , Factores de Riesgo
20.
Exp Clin Transplant ; 15(1): 106-109, 2017 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-26134882

RESUMEN

We present a 24-year-old man who developed primary cytomegalovirus peritonitis without gut perforation, but with concomitant colitis 6 weeks after liver transplant from a deceased donor for end-stage liver disease because of primary sclerosing cholangitis. The patient was treated only medically, with no need for surgery, and is well at 12 months. This case represents the need for suspicious for cytomegalovirus peritonitis in the appropriate setting in post liver transplant even in the absence of perforation.


Asunto(s)
Colangitis Esclerosante/complicaciones , Colitis/virología , Infecciones por Citomegalovirus/virología , Citomegalovirus/aislamiento & purificación , Enfermedad Hepática en Estado Terminal/cirugía , Trasplante de Hígado/efectos adversos , Peritonitis/virología , Administración Intravenosa , Aloinjertos , Antivirales/administración & dosificación , Colangitis Esclerosante/diagnóstico , Colitis/diagnóstico , Colitis/tratamiento farmacológico , Citomegalovirus/efectos de los fármacos , Infecciones por Citomegalovirus/diagnóstico , Infecciones por Citomegalovirus/tratamiento farmacológico , Enfermedad Hepática en Estado Terminal/diagnóstico , Enfermedad Hepática en Estado Terminal/etiología , Ganciclovir/administración & dosificación , Humanos , Masculino , Peritonitis/diagnóstico , Peritonitis/tratamiento farmacológico , Resultado del Tratamiento , Adulto Joven
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA